CEDARS-SINAI MEDICAL CENTER
- Type
- Teaching hospital
- Where
- West Hollywood, CA
- Medicare CCN
- 050625
- Received
- $21,872,671 in 1,492 records, 2025 ($7,289,919 general, $14,582,751 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 317 | $7,289,919 |
| 2025 | Research payment | 1,175 | $14,582,751 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,175 | $14,582,751 |
| Grant | 92 | $3,422,153 |
| Royalty or License | 15 | $2,430,539 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 37 | $580,639 |
| Space rental or facility fees (teaching hospital only) | 93 | $376,710 |
| Education | 14 | $198,834 |
| Long term medical supply or device loan | 18 | $128,876 |
| Charitable Contribution | 3 | $115,500 |
| Debt forgiveness | 44 | $34,179 |
| Honoraria | 1 | $2,488 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $642,399 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $415,741 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $288,752 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib/II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma | 2025 |
| 2025-12-31 | FUJIFILM Healthcare Americas Corporation | $212,181 | Research payment | In-kind items and services | FUJIFILM Device, Medical Device | Prospective Registry of Shear Wave Elastography for the Pancreas using Endoscopic Ultrasound | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $180,119 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $165,780 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $153,363 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition | 2025 |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $145,463 | Research payment | In-kind items and services | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | Cardiac RADIoablation versus repeat catheter Ablation: a pivotal randomized clinical Trial Evaluating safety and efficac | 2025 |
| 2025-12-31 | FUJIFILM Healthcare Americas Corporation | $102,449 | Research payment | In-kind items and services | FUJIFILM Device, Medical Device | Repository of ELUXEO Vision Endoscopic Assessment of Tissue Oxygen Saturation (StO2) Levels (REVEAL Study) | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $101,191 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $71,685 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $70,024 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants W | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $69,460 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | AngioDynamics, Inc. | $44,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $14,701 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2025 |
| 2025-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $11,878 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $10,951 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $10,631 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $9,204 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2025 |
| 2025-12-31 | Stryker Corporation | $6,442 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2025 | |
| 2025-12-31 | Stryker Corporation | $6,353 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,631 | Research payment | In-kind items and services | DOCETAXEL Drug, ONCOLOGY | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista | 2025 |
| 2025-12-31 | Stryker Corporation | $4,740 | Long term medical supply or device loan | In-kind items and services | Bone Mill Plus Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Edwards Lifesciences Corporation | $4,600 | Research payment | Cash or cash equivalent | Prospective, single-arm, EFS for the treatment of subjects with moderate-severe or severe symptomatic mitral valve regur | 2025 | |
| 2025-12-31 | Vapotherm Inc | $4,558 | Long term medical supply or device loan | In-kind items and services | VAPOTHERM Device, RESPIRATORY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $4,253 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2025 |
| 2025-12-31 | Stryker Corporation | $3,808 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,716 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $2,529 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2025 |
| 2025-12-31 | Stryker Corporation | $1,860 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | iRhythm Technologies, Inc. | $1,775 | Research payment | In-kind items and services | ZIO XT Patch Device, Cardiology/Vascular Diseases | STUDY-CTSN PRIMARY TRIAL (CAROL-ACT) | 2025 |
| 2025-12-31 | Stryker Corporation | $1,727 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Immucor, Inc. | $1,310 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | Stryker Corporation | $1,039 | Long term medical supply or device loan | In-kind items and services | SPY-PHI System Device, ENDOSCOPY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $997 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 3, Randomized, Double-blind, Study of Belzutifan Zanzalintinib Versus Belzutifan Placebo in Participants with | 2025 |
| 2025-12-31 | Viseon, Inc. | $804 | Debt forgiveness | In-kind items and services | MaxView System - Lateral Set Device, Spinal Surgery | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $787 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $106 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | Olympus America Inc. | $21 | Debt forgiveness | In-kind items and services | Device | 2025 | |
| 2025-12-31 | Thermo Fisher Scientific Asheville LLC | $15 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | Synthes GmbH | $20,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | Synthes GmbH | $6,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | Medtronic, Inc. | $810 | Research payment | Cash or cash equivalent | NELLCOR Device, Pulse Oximetry | Pulse Ox L&D Pivotal | 2025 |
| 2025-12-29 | Synthes GmbH | $25,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | Janssen Research & Development, LLC | $3,250 | Research payment | Cash or cash equivalent | SIMPONI Biological, Immunology | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | $2,127 | Research payment | Cash or cash equivalent | SIMPONI Biological, Immunology | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | $877 | Research payment | Cash or cash equivalent | An Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli | 2025 | |
| 2025-12-29 | Janssen Research & Development, LLC | $455 | Research payment | Cash or cash equivalent | An Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Deli | 2025 | |
| 2025-12-24 | Daiichi Sankyo Inc. | $9,287 | Research payment | Cash or cash equivalent | U31402-A-U201 | 2025 | |
| 2025-12-24 | United Therapeutics Corporation | $5,616 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $5,497 | Research payment | Cash or cash equivalent | REMODULIN Drug, Pulmonary Arterial Hypertension | A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY A | 2025 |
| 2025-12-23 | Edwards Lifesciences Corporation | $9,486 | Research payment | Cash or cash equivalent | Prospective, single-arm, EFS for the treatment of subjects with moderate-severe or severe symptomatic mitral valve regur | 2025 | |
| 2025-12-23 | Edwards Lifesciences Corporation | $5,294 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2025 | |
| 2025-12-22 | Janssen Research & Development, LLC | $26,773 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $13,000 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $5,200 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $4,832 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $4,550 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $3,640 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $3,553 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $3,449 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-902 | 2025 |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $3,347 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Eidos Therapeutics, Inc. | $2,210 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin | 2025 |
| 2025-12-22 | PFIZER INC. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $1,878 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $1,250 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $586 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $586 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $455 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Regeneron Pharmaceuticals, Inc. | $455 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL FOR A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN9933 AND REGN7508, MONOCLONAL | 2025 | |
| 2025-12-22 | Genmab A/S | $442 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2025 |
| 2025-12-22 | BioMarin Pharmaceutical Inc. | $325 | Research payment | Cash or cash equivalent | VOXZOGO 1.2mg Drug, Achondroplasia | BMN 111-902 | 2025 |
| 2025-12-21 | FUJIFILM Healthcare Americas Corporation | $6,950 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FUJIFILM Device, Medical Device | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $21,600 | Research payment | Cash or cash equivalent | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $17,415 | Research payment | Cash or cash equivalent | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat | 2025 | |
| 2025-12-19 | AstraZeneca Pharmaceuticals LP | $7,792 | Research payment | Cash or cash equivalent | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2025 | |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $7,493 | Research payment | Cash or cash equivalent | ENTYVIO Biological, INTERNAL MEDICINE | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $5,427 | Research payment | Cash or cash equivalent | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $3,500 | Research payment | Cash or cash equivalent | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat | 2025 | |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | $3,375 | Research payment | Cash or cash equivalent | Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16CD3 Bispecific Antibody) With or Without Additional Agents in Plat | 2025 | |
| 2025-12-19 | Janssen Research & Development, LLC | $3,010 | Research payment | Cash or cash equivalent | SIMPONI Biological, Immunology | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-19 | Genentech, Inc. | $3,002 | Research payment | Cash or cash equivalent | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 | |
| 2025-12-19 | Janssen Research & Development, LLC | $400 | Research payment | Cash or cash equivalent | SIMPONI Biological, Immunology | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | $239 | Research payment | Cash or cash equivalent | SIMPONI Biological, Immunology | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-19 | Ethicon Endo-Surgery Inc. | $194 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2025 |
| 2025-12-18 | Boston Scientific Corporation | $35,000 | Grant | Cash or cash equivalent | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-18 | Recor Medical Inc | $8,385 | Research payment | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | RADIANCE CAP | 2025 |
| 2025-12-18 | Boston Scientific Corporation | $6,950 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-18 | Recor Medical Inc | $2,470 | Research payment | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | RADIANCE CAP | 2025 |
| 2025-12-18 | Travere Therapeutics, Inc. | $845 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-12-17 | Merck Sharp & Dohme LLC | $186,826 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2025 |
| 2025-12-17 | Novocure GmbH | $54,881 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2025 | |
| 2025-12-17 | Synthes GmbH | $7,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Novocure GmbH | $4,550 | Research payment | Cash or cash equivalent | EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiat | 2025 | |
| 2025-12-17 | Olympus Corporation of the Americas | $4,000 | Grant | In-kind items and services | EVIS EXERA III DUODENOVIDEOSCOPE Device, Gastroenterology | 2025 | |
| 2025-12-16 | Boston Scientific Corporation | $11,550 | Research payment | Cash or cash equivalent | Vercise Device, Vercise_NMD | US DBS REGISTRY | 2025 |
| 2025-12-16 | Premia Spine, Ltd. | $4,160 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2025 |
| 2025-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,300 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-16 | Boston Scientific Corporation | $1,034 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | ELEGANCE | 2025 |
| 2025-12-16 | Madrigal Pharmaceuticals | $130 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-12-16 | Boston Scientific Corporation | $13 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | ACURATE IDE | 2025 |
| 2025-12-15 | Merck Sharp & Dohme LLC | $80,310 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-15 | Olympus Corporation of the Americas | $20,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-15 | Edwards Lifesciences Corporation | $1,820 | Research payment | Cash or cash equivalent | ALTERRA Early Feasibility (2016-04) | 2025 | |
| 2025-12-15 | Edwards Lifesciences Corporation | $1,241 | Research payment | Cash or cash equivalent | JOURNEY (Trial JCM-002) | 2025 | |
| 2025-12-12 | Genentech, Inc. | $11,886 | Research payment | Cash or cash equivalent | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | 2025 | |
| 2025-12-12 | Stryker Corporation | $5,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | Medtronic, Inc. | $2,785 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-12-12 | Lexicon Pharmaceuticals, Inc. | $2,202 | Research payment | Cash or cash equivalent | SONATA-HCM | 2025 | |
| 2025-12-12 | Gilead Sciences, Inc. | $780 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-12-11 | Boston Scientific Corporation | $2,137,452 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-11 | Edwards Lifesciences Corporation | $6,607 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-12-11 | PFIZER INC. | $3,167 | Research payment | Cash or cash equivalent | A LOWINTERVENTIONAL STUDY TO ASSESS PHYSICAL ACTIVITY USING DIGITAL HEALTH TECHNOLOGY IN ADULT PARTICIPANTS WITH CACHEXI | 2025 | |
| 2025-12-11 | Janssen Research & Development, LLC | $2,400 | Research payment | Cash or cash equivalent | REMICADE Biological, Immunology | A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEV | 2025 |
| 2025-12-11 | Edwards Lifesciences Corporation | $2,276 | Research payment | Cash or cash equivalent | ALTERRA Post-Approval Study 2021-11 | 2025 | |
| 2025-12-10 | Edwards Lifesciences Corporation | $176,599 | Research payment | Cash or cash equivalent | The PROGRESS Trial – Continued Access 2021-01-CAP | 2025 | |
| 2025-12-10 | Edwards Lifesciences Corporation | $71,283 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2025 | |
| 2025-12-10 | Merck Sharp & Dohme LLC | $42,749 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2025 |
| 2025-12-10 | Ionis Pharmaceuticals, Inc. | $25,650 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-12-10 | Vapotherm Inc | $24,220 | Long term medical supply or device loan | In-kind items and services | VAPOTHERM Device, RESPIRATORY | 2025 | |
| 2025-12-10 | Gilead Sciences, Inc. | $19,110 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-12-10 | Cook Incorporated | $5,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | Gilead Sciences, Inc. | $3,500 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-12-10 | Ionis Pharmaceuticals, Inc. | $3,000 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-12-10 | Ionis Pharmaceuticals, Inc. | $2,700 | Research payment | Cash or cash equivalent | ION582P3 | 2025 | |
| 2025-12-10 | Abbott Laboratories | $2,650 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-12-10 | Abbott Laboratories | $1,950 | Research payment | Cash or cash equivalent | Device, Structural Heart | NCT06223789--VOLT-AF IDE Clinical Study | 2025 |
| 2025-12-10 | Gilead Sciences, Inc. | $1,950 | Research payment | Cash or cash equivalent | Livdelzi Drug, INFLAM | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patien | 2025 |
| 2025-12-10 | Mannkind Corporation | $650 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-12-10 | Sumitomo Pharma America, Inc. | $1 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-09 | Gilead Sciences, Inc. | $100,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | PFIZER INC. | $57,300 | Research payment | In-kind items and services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $11,676 | Research payment | Cash or cash equivalent | VPRIV Biological, GENETIC DISEASE | GAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH G | 2025 |
| 2025-12-09 | Medical Device Business Services, Inc. | $10,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | COLOPLAST CORP | $2,774 | Research payment | Cash or cash equivalent | INTIBIA | 2025 | |
| 2025-12-09 | Boston Scientific Corporation | $1,005 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | AGENT IDE | 2025 |
| 2025-12-09 | PFIZER INC. | $7 | Research payment | In-kind items and services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-12-08 | Ultragenyx Pharmaceutical Inc. | $80,840 | Research payment | Cash or cash equivalent | GTX-102-CL301 | 2025 | |
| 2025-12-08 | SANOFI US SERVICES INC. | $37,912 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safet | 2025 | |
| 2025-12-08 | PFIZER INC. | $34,651 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-12-08 | Ascendis Pharma Endocrinology Inc | $5,642 | Research payment | Cash or cash equivalent | IL Believe | 2025 | |
| 2025-12-08 | PFIZER INC. | $1,750 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-12-08 | Penumbra, Inc. | $358 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2025 |
| 2025-12-08 | ABBVIE INC. | $200 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-12-04 | ABBVIE INC. | $15,634 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-12-04 | Janssen Research & Development, LLC | $5,134 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-12-03 | Merck Sharp & Dohme LLC | $64,980 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants W | 2025 |
| 2025-12-03 | Arthrex, Inc. | $40,000 | Research payment | Cash or cash equivalent | Biomechanical Analysis of SuturePatch Augmentation of Soft-Tissue Repair | 2025 | |
| 2025-12-03 | CSL Behring | $20,550 | Research payment | Cash or cash equivalent | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom | 2025 | |
| 2025-12-03 | Bolton Medical Inc | $17,142 | Research payment | Cash or cash equivalent | THORAFLEX HYBRID Device, ENDOVASCULAR AORTIC REPAIR | EXTEND | 2025 |
| 2025-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,549 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-12-03 | CSL Behring | $3,500 | Research payment | Cash or cash equivalent | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom | 2025 | |
| 2025-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,560 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $267 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $228 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $220 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $158 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $105 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $99 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $99 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $89 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $79 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $64 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $6 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $5 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $4 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-03 | Sumitomo Pharma America, Inc. | $2 | Research payment | In-kind items and services | AN OPEN-LABEL, PHASE 1 DOSE ESCALATION AND PHASE 2 DOSE EXPANSION STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS | 2025 | |
| 2025-12-02 | Madrigal Pharmaceuticals | $17,247 | Research payment | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOL | 2025 |
| 2025-12-02 | Cochlear Americas | $15 | Debt forgiveness | Cash or cash equivalent | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2025 | |
| 2025-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $3,967 | Research payment | Cash or cash equivalent | An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous ( | 2025 | |
| 2025-12-01 | Travere Therapeutics, Inc. | $3,924 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2025 | |
| 2025-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $2,531 | Research payment | Cash or cash equivalent | Vedolizumab-4054 A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2025 | |
| 2025-11-28 | Edwards Lifesciences Corporation | $7,500 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2025 | |
| 2025-11-28 | Boston Scientific Corporation | $2,995 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-11-28 | Edwards Lifesciences Corporation | $2,346 | Research payment | Cash or cash equivalent | SM3 Trial 2017-03 | 2025 | |
| 2025-11-28 | Edwards Lifesciences Corporation | $234 | Research payment | Cash or cash equivalent | COMPASSION S3 Post Approval Study (2020-07) | 2025 | |
| 2025-11-27 | Janssen Research & Development, LLC | $2,895 | Research payment | Cash or cash equivalent | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatm | 2025 | |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $35,130 | Research payment | Cash or cash equivalent | A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors | 2025 | |
| 2025-11-26 | Orthofix Medical, Inc. | $4,802 | Research payment | Cash or cash equivalent | FBBT, HPCS, OPHR | 2025 | |
| 2025-11-26 | PFIZER INC. | $1,233 | Research payment | Cash or cash equivalent | A LOWINTERVENTIONAL STUDY TO ASSESS PHYSICAL ACTIVITY USING DIGITAL HEALTH TECHNOLOGY IN ADULT PARTICIPANTS WITH CACHEXI | 2025 | |
| 2025-11-25 | KLS-Martin L.P. | $547 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE, CLAMP, REDUCTION, BONE, SHARP, 15 CM, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-11-24 | CSL Behring | $2,985 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-24 | Integra LifeSciences Corporation | $1,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-24 | PFIZER INC. | $15 | Research payment | In-kind items and services | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITO | 2025 | |
| 2025-11-21 | Genmab A/S | $2,830 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2025 |
| 2025-11-21 | GENZYME CORPORATION | $2,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CERDELGA Drug, Genetic Disease | 2025 | |
| 2025-11-21 | Eidos Therapeutics, Inc. | $323 | Research payment | Cash or cash equivalent | Attruby Drug, Cardiomyopathy | An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin | 2025 |
| 2025-11-20 | Arthrex, Inc. | $7,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | ABBVIE INC. | $6,725 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric P | 2025 |
| 2025-11-20 | Globus Medical, Inc. | $3,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | CSL Behring | $105 | Research payment | In-kind items and services | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom | 2025 | |
| 2025-11-19 | PFIZER INC. | $46,207 | Research payment | In-kind items and services | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2025 |
| 2025-11-19 | Musculoskeletal Transplant Foundation Inc. | $3,839 | Research payment | Cash or cash equivalent | IPA The Effect of Reticular Meshed Dermal ALlograft on Wound Healing | 2025 | |
| 2025-11-19 | Abbott Laboratories | $1,467 | Research payment | Cash or cash equivalent | PORTICO Device, Structural Heart | NCT04011722--Portico Next Generation Approval Study | 2025 |
| 2025-11-19 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2025 |
The latest 200 records of 1,492.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) West Hollywood, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 34,884 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 35,757 | 10,014,009 | 39,538,223 |
| Median age B01002 | 40.0 | 38.2 | 37.9 |
| Under 18 B01001 | 3.6% | 20.6% | 22.0% |
| 65 and over B01001 | 16.8% | 15.2% | 15.7% |
| Households B11001 | 22,920 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 23.6% | 33.4% | 27.0% |
| Median household income B19013 | $96,995 | $90,112 | $99,122 |
| Median family income B19113 | $126,364 | $101,573 | $113,346 |
| Per capita income B19301 | $90,080 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.9% | 7.3% | 6.6% |
| Civilian labor force B23025 | 25,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 64.2% | 36.0% | 37.1% |
| Housing units B25001 | 26,079 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 19.8% | 45.9% | 55.9% |
| Renters B25003 | 80.2% | 54.1% | 44.1% |
| Median home value B25077 | $924,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,091 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 69.5% | 24.7% | 33.8% |
| Black B03002 | 4.3% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 13.1% | 48.4% | 40.2% |
| Asian B03002 | 6.1% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.
Comments